Mesoblast Limited (MEOBF)
MEOBF Stock Price Chart
Explore Mesoblast Limited interactive price chart. Choose custom timeframes to analyze MEOBF price movements and trends.
MEOBF Company Profile
Discover essential business fundamentals and corporate details for Mesoblast Limited (MEOBF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
15 Oct 2010
Employees
73.00
Website
https://www.mesoblast.comCEO
Silviu Itescu FACP, FACRA, FRACP, MBBS
Description
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
MEOBF Financial Timeline
Browse a chronological timeline of Mesoblast Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 25 Feb 2026
Earnings released on 28 Aug 2025
EPS came in at -$0.04 falling short of the estimated -$0.04 by -17.73%, while revenue for the quarter reached $14.00M , missing expectations by -42.52%.
Earnings released on 30 Apr 2025
Earnings released on 26 Feb 2025
EPS came in at -$0.04 surpassing the estimated -$0.05 by +14.29%, while revenue for the quarter reached $3.20M , missing expectations by -57.23%.
Earnings released on 30 Oct 2024
Earnings released on 29 Aug 2024
EPS came in at -$0.02 surpassing the estimated -$0.04 by +30.03%, while revenue for the quarter reached $1.26M , missing expectations by -69.31%.
Earnings released on 31 Mar 2024
EPS came in at -$0.02 , while revenue for the quarter reached $1.26M .
Earnings released on 29 Feb 2024
EPS came in at -$0.02 surpassing the estimated -$0.04 by +55.19%, while revenue for the quarter reached $1.69M , missing expectations by -56.22%.
Stock split effective on 11 Dec 2023
Shares were split 527 : 500 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Sept 2023
EPS came in at -$0.02 surpassing the estimated -$0.03 by +30.99%, while revenue for the quarter reached $1.69M , missing expectations by -28.93%.
Earnings released on 30 Jun 2023
EPS came in at -$0.03 , while revenue for the quarter reached $2.13M .
Earnings released on 31 Mar 2023
EPS came in at -$0.02 surpassing the estimated -$0.03 by +23.95%, while revenue for the quarter reached $1.94M , missing expectations by -9.38%.
Earnings released on 28 Feb 2023
EPS came in at -$0.03 falling short of the estimated -$0.03 by -18.72%, while revenue for the quarter reached $1.98M , missing expectations by -5.71%.
Earnings released on 30 Sept 2022
EPS came in at -$0.02 surpassing the estimated -$0.03 by +21.67%, while revenue for the quarter reached $1.44M , missing expectations by -58.38%.
Earnings released on 31 Aug 2022
EPS came in at -$0.03 falling short of the estimated -$0.02 by -61.01%, while revenue for the quarter reached $2.22M , missing expectations by -70.71%.
Earnings released on 31 Mar 2022
EPS came in at -$0.03 falling short of the estimated -$0.03 by -28.09%, while revenue for the quarter reached $2.01M , missing expectations by -4.24%.
Earnings released on 26 Feb 2022
EPS came in at -$0.04 falling short of the estimated -$0.04 by -3.81%, while revenue for the quarter reached $2.38M , missing expectations by -31.94%.
Earnings released on 30 Sept 2021
EPS came in at -$0.03 , while revenue for the quarter reached $3.59M .
Earnings released on 30 Jun 2021
EPS came in at -$0.03 , while revenue for the quarter reached $2.00M .
Earnings released on 4 Jun 2021
EPS came in at -$0.04 , while revenue for the quarter reached $1.91M .
Earnings released on 4 Jun 2021
EPS came in at -$0.04 , while revenue for the quarter reached $2.24M .
Earnings released on 30 Sept 2020
EPS came in at -$0.04 , while revenue for the quarter reached $1.29M .
MEOBF Stock Performance
Access detailed MEOBF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.